Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Growth 2022-2028
The report requires updating with new data and is sent in 48 hours after order is placed.
As the global economy mends, the 2021 growth of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine will have significant change from previous year. According to our (LP Information) latest study, the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, reaching US$ million by the year 2028. As for the Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine players cover Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, and Novartis AG, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
As the global economy mends, the 2021 growth of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine will have significant change from previous year. According to our (LP Information) latest study, the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, reaching US$ million by the year 2028. As for the Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine players cover Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, and Novartis AG, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
- Immune DTaP Vaccine
- Therapy DTaP Vaccine
- Adult
- Pediatric
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sanofi Pasteur
- GlaxoSmithKline
- Protein Sciences Corporation
- Novartis AG
- Seqirus
- Merck Sharp & Dohme Corp
- Astellas Pharma US
- Pfizer Inc
- Johnson & Johnson
- Lanzhou Institute of Biological Products Co., Ltd
- AstraZeneca
- Emergent BioSolutions Inc
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Country/Region, 2017, 2022 & 2028
2.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Type
2.2.1 Immune DTaP Vaccine
2.2.2 Therapy DTaP Vaccine
2.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
2.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2022)
2.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Market Share by Type (2017-2022)
2.3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sale Price by Type (2017-2022)
2.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Application
2.4.1 Adult
2.4.2 Pediatric
2.5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
2.5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sale Market Share by Application (2017-2022)
2.5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Market Share by Application (2017-2022)
2.5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sale Price by Application (2017-2022)
3 GLOBAL DIPHTHERIA, TETANUS, AND PERTUSSIS (DTAP) VACCINE BY COMPANY
3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Breakdown Data by Company
3.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Sales by Company (2020-2022)
3.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Company (2020-2022)
3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Revenue by Company (2020-2022)
3.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2020-2022)
3.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Company (2020-2022)
3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sale Price by Company
3.4 Key Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Location Distribution
3.4.2 Players Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR DIPHTHERIA, TETANUS, AND PERTUSSIS (DTAP) VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Geographic Region (2017-2022)
4.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Revenue by Geographic Region
4.2 World Historic Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country/Region (2017-2022)
4.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Sales by Country/Region (2017-2022)
4.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Revenue by Country/Region
4.3 Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth
4.4 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth
4.5 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth
4.6 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth
5 AMERICAS
5.1 Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country
5.1.1 Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022)
5.1.2 Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022)
5.2 Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
5.3 Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region
6.1.1 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022)
6.1.2 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022)
6.2 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
6.3 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Country
7.1.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022)
7.1.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022)
7.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
7.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Country
8.1.1 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022)
8.1.2 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022)
8.2 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
8.3 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
10.3 Manufacturing Process Analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
10.4 Industry Chain Structure of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
11.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customer
12 WORLD FORECAST REVIEW FOR DIPHTHERIA, TETANUS, AND PERTUSSIS (DTAP) VACCINE BY GEOGRAPHIC REGION
12.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Forecast by Region
12.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecast by Region (2023-2028)
12.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecast by Type
12.7 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Sanofi Pasteur
13.1.1 Sanofi Pasteur Company Information
13.1.2 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Sanofi Pasteur Main Business Overview
13.1.5 Sanofi Pasteur Latest Developments
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Information
13.2.2 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.2.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 GlaxoSmithKline Main Business Overview
13.2.5 GlaxoSmithKline Latest Developments
13.3 Protein Sciences Corporation
13.3.1 Protein Sciences Corporation Company Information
13.3.2 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.3.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Protein Sciences Corporation Main Business Overview
13.3.5 Protein Sciences Corporation Latest Developments
13.4 Novartis AG
13.4.1 Novartis AG Company Information
13.4.2 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.4.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Novartis AG Main Business Overview
13.4.5 Novartis AG Latest Developments
13.5 Seqirus
13.5.1 Seqirus Company Information
13.5.2 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.5.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Seqirus Main Business Overview
13.5.5 Seqirus Latest Developments
13.6 Merck Sharp & Dohme Corp
13.6.1 Merck Sharp & Dohme Corp Company Information
13.6.2 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.6.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Merck Sharp & Dohme Corp Main Business Overview
13.6.5 Merck Sharp & Dohme Corp Latest Developments
13.7 Astellas Pharma US
13.7.1 Astellas Pharma US Company Information
13.7.2 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.7.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Astellas Pharma US Main Business Overview
13.7.5 Astellas Pharma US Latest Developments
13.8 Pfizer Inc
13.8.1 Pfizer Inc Company Information
13.8.2 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.8.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Pfizer Inc Main Business Overview
13.8.5 Pfizer Inc Latest Developments
13.9 Johnson & Johnson
13.9.1 Johnson & Johnson Company Information
13.9.2 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.9.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Johnson & Johnson Main Business Overview
13.9.5 Johnson & Johnson Latest Developments
13.10 Lanzhou Institute of Biological Products Co., Ltd
13.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
13.10.2 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Lanzhou Institute of Biological Products Co., Ltd Main Business Overview
13.10.5 Lanzhou Institute of Biological Products Co., Ltd Latest Developments
13.11 AstraZeneca
13.11.1 AstraZeneca Company Information
13.11.2 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.11.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 AstraZeneca Main Business Overview
13.11.5 AstraZeneca Latest Developments
13.12 Emergent BioSolutions Inc
13.12.1 Emergent BioSolutions Inc Company Information
13.12.2 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.12.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Emergent BioSolutions Inc Main Business Overview
13.12.5 Emergent BioSolutions Inc Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Country/Region, 2017, 2022 & 2028
2.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Type
2.2.1 Immune DTaP Vaccine
2.2.2 Therapy DTaP Vaccine
2.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
2.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2022)
2.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Market Share by Type (2017-2022)
2.3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sale Price by Type (2017-2022)
2.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Application
2.4.1 Adult
2.4.2 Pediatric
2.5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
2.5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sale Market Share by Application (2017-2022)
2.5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue and Market Share by Application (2017-2022)
2.5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sale Price by Application (2017-2022)
3 GLOBAL DIPHTHERIA, TETANUS, AND PERTUSSIS (DTAP) VACCINE BY COMPANY
3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Breakdown Data by Company
3.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Sales by Company (2020-2022)
3.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Company (2020-2022)
3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Revenue by Company (2020-2022)
3.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2020-2022)
3.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Company (2020-2022)
3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sale Price by Company
3.4 Key Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Location Distribution
3.4.2 Players Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR DIPHTHERIA, TETANUS, AND PERTUSSIS (DTAP) VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Geographic Region (2017-2022)
4.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Revenue by Geographic Region
4.2 World Historic Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country/Region (2017-2022)
4.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Sales by Country/Region (2017-2022)
4.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Revenue by Country/Region
4.3 Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth
4.4 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth
4.5 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth
4.6 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth
5 AMERICAS
5.1 Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country
5.1.1 Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022)
5.1.2 Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022)
5.2 Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
5.3 Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region
6.1.1 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022)
6.1.2 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022)
6.2 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
6.3 APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Country
7.1.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022)
7.1.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022)
7.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
7.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Country
8.1.1 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022)
8.1.2 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022)
8.2 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
8.3 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
10.3 Manufacturing Process Analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
10.4 Industry Chain Structure of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
11.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customer
12 WORLD FORECAST REVIEW FOR DIPHTHERIA, TETANUS, AND PERTUSSIS (DTAP) VACCINE BY GEOGRAPHIC REGION
12.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Forecast by Region
12.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecast by Region (2023-2028)
12.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecast by Type
12.7 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Sanofi Pasteur
13.1.1 Sanofi Pasteur Company Information
13.1.2 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Sanofi Pasteur Main Business Overview
13.1.5 Sanofi Pasteur Latest Developments
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Information
13.2.2 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.2.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 GlaxoSmithKline Main Business Overview
13.2.5 GlaxoSmithKline Latest Developments
13.3 Protein Sciences Corporation
13.3.1 Protein Sciences Corporation Company Information
13.3.2 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.3.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Protein Sciences Corporation Main Business Overview
13.3.5 Protein Sciences Corporation Latest Developments
13.4 Novartis AG
13.4.1 Novartis AG Company Information
13.4.2 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.4.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Novartis AG Main Business Overview
13.4.5 Novartis AG Latest Developments
13.5 Seqirus
13.5.1 Seqirus Company Information
13.5.2 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.5.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Seqirus Main Business Overview
13.5.5 Seqirus Latest Developments
13.6 Merck Sharp & Dohme Corp
13.6.1 Merck Sharp & Dohme Corp Company Information
13.6.2 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.6.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Merck Sharp & Dohme Corp Main Business Overview
13.6.5 Merck Sharp & Dohme Corp Latest Developments
13.7 Astellas Pharma US
13.7.1 Astellas Pharma US Company Information
13.7.2 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.7.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Astellas Pharma US Main Business Overview
13.7.5 Astellas Pharma US Latest Developments
13.8 Pfizer Inc
13.8.1 Pfizer Inc Company Information
13.8.2 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.8.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Pfizer Inc Main Business Overview
13.8.5 Pfizer Inc Latest Developments
13.9 Johnson & Johnson
13.9.1 Johnson & Johnson Company Information
13.9.2 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.9.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Johnson & Johnson Main Business Overview
13.9.5 Johnson & Johnson Latest Developments
13.10 Lanzhou Institute of Biological Products Co., Ltd
13.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
13.10.2 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Lanzhou Institute of Biological Products Co., Ltd Main Business Overview
13.10.5 Lanzhou Institute of Biological Products Co., Ltd Latest Developments
13.11 AstraZeneca
13.11.1 AstraZeneca Company Information
13.11.2 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.11.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 AstraZeneca Main Business Overview
13.11.5 AstraZeneca Latest Developments
13.12 Emergent BioSolutions Inc
13.12.1 Emergent BioSolutions Inc Company Information
13.12.2 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
13.12.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Emergent BioSolutions Inc Main Business Overview
13.12.5 Emergent BioSolutions Inc Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Immune DTaP Vaccine
Table 4. Major Players of Therapy DTaP Vaccine
Table 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2022)
Table 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & ($ million)
Table 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2022)
Table 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sale Price by Type (2017-2022) & (USD/Dose)
Table 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2022)
Table 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022)
Table 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2022)
Table 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sale Price by Application (2017-2022) & (USD/Dose)
Table 15. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Company (2020-2022) & (K Doses)
Table 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Company (2020-2022)
Table 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Company (2020-2022)
Table 19. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sale Price by Company (2020-2022) & (USD/Dose)
Table 20. Key Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Producing Area Distribution and Sales Area
Table 21. Players Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
Table 22. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Geographic Region (2017-2022) & (K Doses)
Table 26. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share Geographic Region (2017-2022)
Table 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country/Region (2017-2022) & (K Doses)
Table 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country/Region (2017-2022)
Table 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 34. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2017-2022)
Table 35. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2017-2022)
Table 37. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 38. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2022)
Table 39. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 40. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2022)
Table 41. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022) & (K Doses)
Table 42. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2022)
Table 43. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2017-2022)
Table 45. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 46. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2022)
Table 47. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 48. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2022)
Table 49. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 50. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2017-2022)
Table 51. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2017-2022)
Table 53. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 54. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2022)
Table 55. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 56. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 58. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 62. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 64. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Table 66. Key Market Challenges & Risks of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Table 67. Key Industry Trends of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Table 68. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors List
Table 71. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customer List
Table 72. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Region (2023-2028) & (K Doses)
Table 73. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Forecast by Region
Table 74. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 77. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Region (2023-2028) & (K Doses)
Table 79. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 81. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 83. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Type (2023-2028) & (K Doses)
Table 85. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Application (2023-2028) & (K Doses)
Table 89. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share Forecast by Application (2023-2028)
Table 92. Sanofi Pasteur Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 94. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 95. Sanofi Pasteur Main Business
Table 96. Sanofi Pasteur Latest Developments
Table 97. GlaxoSmithKline Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 99. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 100. GlaxoSmithKline Main Business
Table 101. GlaxoSmithKline Latest Developments
Table 102. Protein Sciences Corporation Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 104. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 105. Protein Sciences Corporation Main Business
Table 106. Protein Sciences Corporation Latest Developments
Table 107. Novartis AG Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 109. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 110. Novartis AG Main Business
Table 111. Novartis AG Latest Developments
Table 112. Seqirus Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 114. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 115. Seqirus Main Business
Table 116. Seqirus Latest Developments
Table 117. Merck Sharp & Dohme Corp Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 119. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 120. Merck Sharp & Dohme Corp Main Business
Table 121. Merck Sharp & Dohme Corp Latest Developments
Table 122. Astellas Pharma US Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 123. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 124. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 125. Astellas Pharma US Main Business
Table 126. Astellas Pharma US Latest Developments
Table 127. Pfizer Inc Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 128. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 129. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 130. Pfizer Inc Main Business
Table 131. Pfizer Inc Latest Developments
Table 132. Johnson & Johnson Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 133. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 134. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 135. Johnson & Johnson Main Business
Table 136. Johnson & Johnson Latest Developments
Table 137. Lanzhou Institute of Biological Products Co., Ltd Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 138. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 139. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 140. Lanzhou Institute of Biological Products Co., Ltd Main Business
Table 141. Lanzhou Institute of Biological Products Co., Ltd Latest Developments
Table 142. AstraZeneca Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 143. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 144. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 145. AstraZeneca Main Business
Table 146. AstraZeneca Latest Developments
Table 147. Emergent BioSolutions Inc Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 148. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 149. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 150. Emergent BioSolutions Inc Main Business
Table 151. Emergent BioSolutions Inc Latest Developments
Table 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Immune DTaP Vaccine
Table 4. Major Players of Therapy DTaP Vaccine
Table 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2022)
Table 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2022) & ($ million)
Table 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2022)
Table 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sale Price by Type (2017-2022) & (USD/Dose)
Table 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2022)
Table 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2022)
Table 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2017-2022)
Table 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sale Price by Application (2017-2022) & (USD/Dose)
Table 15. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Company (2020-2022) & (K Doses)
Table 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Company (2020-2022)
Table 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Company (2020-2022)
Table 19. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sale Price by Company (2020-2022) & (USD/Dose)
Table 20. Key Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Producing Area Distribution and Sales Area
Table 21. Players Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
Table 22. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Geographic Region (2017-2022) & (K Doses)
Table 26. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share Geographic Region (2017-2022)
Table 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country/Region (2017-2022) & (K Doses)
Table 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country/Region (2017-2022)
Table 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 34. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2017-2022)
Table 35. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2017-2022)
Table 37. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 38. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2022)
Table 39. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 40. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2022)
Table 41. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2017-2022) & (K Doses)
Table 42. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2022)
Table 43. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2017-2022)
Table 45. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 46. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2022)
Table 47. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 48. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2022)
Table 49. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 50. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2017-2022)
Table 51. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2017-2022)
Table 53. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 54. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2022)
Table 55. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 56. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2017-2022) & (K Doses)
Table 58. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2022) & (K Doses)
Table 62. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2022) & (K Doses)
Table 64. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Table 66. Key Market Challenges & Risks of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Table 67. Key Industry Trends of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Table 68. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors List
Table 71. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customer List
Table 72. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Region (2023-2028) & (K Doses)
Table 73. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Forecast by Region
Table 74. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 77. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Region (2023-2028) & (K Doses)
Table 79. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 81. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 83. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Type (2023-2028) & (K Doses)
Table 85. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Application (2023-2028) & (K Doses)
Table 89. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share Forecast by Application (2023-2028)
Table 92. Sanofi Pasteur Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 94. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 95. Sanofi Pasteur Main Business
Table 96. Sanofi Pasteur Latest Developments
Table 97. GlaxoSmithKline Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 99. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 100. GlaxoSmithKline Main Business
Table 101. GlaxoSmithKline Latest Developments
Table 102. Protein Sciences Corporation Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 104. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 105. Protein Sciences Corporation Main Business
Table 106. Protein Sciences Corporation Latest Developments
Table 107. Novartis AG Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 109. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 110. Novartis AG Main Business
Table 111. Novartis AG Latest Developments
Table 112. Seqirus Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 114. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 115. Seqirus Main Business
Table 116. Seqirus Latest Developments
Table 117. Merck Sharp & Dohme Corp Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 119. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 120. Merck Sharp & Dohme Corp Main Business
Table 121. Merck Sharp & Dohme Corp Latest Developments
Table 122. Astellas Pharma US Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 123. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 124. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 125. Astellas Pharma US Main Business
Table 126. Astellas Pharma US Latest Developments
Table 127. Pfizer Inc Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 128. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 129. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 130. Pfizer Inc Main Business
Table 131. Pfizer Inc Latest Developments
Table 132. Johnson & Johnson Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 133. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 134. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 135. Johnson & Johnson Main Business
Table 136. Johnson & Johnson Latest Developments
Table 137. Lanzhou Institute of Biological Products Co., Ltd Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 138. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 139. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 140. Lanzhou Institute of Biological Products Co., Ltd Main Business
Table 141. Lanzhou Institute of Biological Products Co., Ltd Latest Developments
Table 142. AstraZeneca Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 143. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 144. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 145. AstraZeneca Main Business
Table 146. AstraZeneca Latest Developments
Table 147. Emergent BioSolutions Inc Basic Information, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 148. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
Table 149. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2022)
Table 150. Emergent BioSolutions Inc Main Business
Table 151. Emergent BioSolutions Inc Latest Developments
LIST OF FIGURES
Figure 1. Picture of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Figure 2. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate 2017-2028 (K Doses)
Figure 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Immune DTaP Vaccine
Figure 10. Product Picture of Therapy DTaP Vaccine
Figure 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type in 2021
Figure 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2022)
Figure 13. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Consumed in Adult
Figure 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market: Adult (2017-2022) & (K Doses)
Figure 15. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Consumed in Pediatric
Figure 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market: Pediatric (2017-2022) & (K Doses)
Figure 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2022)
Figure 18. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application in 2021
Figure 19. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market by Company in 2021 ($ Million)
Figure 20. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Company in 2021
Figure 21. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Geographic Region (2017-2022)
Figure 22. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Geographic Region in 2021
Figure 23. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2022)
Figure 24. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country/Region in 2021
Figure 25. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales 2017-2022 (K Doses)
Figure 26. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue 2017-2022 ($ Millions)
Figure 27. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales 2017-2022 (K Doses)
Figure 28. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue 2017-2022 ($ Millions)
Figure 29. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales 2017-2022 (K Doses)
Figure 30. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue 2017-2022 ($ Millions)
Figure 31. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales 2017-2022 (K Doses)
Figure 32. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue 2017-2022 ($ Millions)
Figure 33. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country in 2021
Figure 34. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country in 2021
Figure 35. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 36. Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 37. Mexico Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 38. Brazil Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 39. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region in 2021
Figure 40. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Regions in 2021
Figure 41. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 42. Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 43. South Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 44. Southeast Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 45. India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 46. Australia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 47. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country in 2021
Figure 48. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country in 2021
Figure 49. Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 50. France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 51. UK Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 52. Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 53. Russia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 54. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country in 2021
Figure 55. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country in 2021
Figure 56. Egypt Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 57. South Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 58. Israel Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 59. Turkey Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 60. GCC Country Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 61. Manufacturing Cost Structure Analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in 2021
Figure 62. Manufacturing Process Analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Figure 63. Industry Chain Structure of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Figure 64. Channels of Distribution
Figure 65. Distributors Profiles
Figure 1. Picture of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Figure 2. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate 2017-2028 (K Doses)
Figure 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Immune DTaP Vaccine
Figure 10. Product Picture of Therapy DTaP Vaccine
Figure 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type in 2021
Figure 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2017-2022)
Figure 13. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Consumed in Adult
Figure 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market: Adult (2017-2022) & (K Doses)
Figure 15. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Consumed in Pediatric
Figure 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market: Pediatric (2017-2022) & (K Doses)
Figure 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2017-2022)
Figure 18. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application in 2021
Figure 19. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market by Company in 2021 ($ Million)
Figure 20. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Company in 2021
Figure 21. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Geographic Region (2017-2022)
Figure 22. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Geographic Region in 2021
Figure 23. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2017-2022)
Figure 24. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country/Region in 2021
Figure 25. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales 2017-2022 (K Doses)
Figure 26. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue 2017-2022 ($ Millions)
Figure 27. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales 2017-2022 (K Doses)
Figure 28. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue 2017-2022 ($ Millions)
Figure 29. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales 2017-2022 (K Doses)
Figure 30. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue 2017-2022 ($ Millions)
Figure 31. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales 2017-2022 (K Doses)
Figure 32. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue 2017-2022 ($ Millions)
Figure 33. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country in 2021
Figure 34. Americas Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country in 2021
Figure 35. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 36. Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 37. Mexico Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 38. Brazil Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 39. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region in 2021
Figure 40. APAC Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Regions in 2021
Figure 41. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 42. Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 43. South Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 44. Southeast Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 45. India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 46. Australia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 47. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country in 2021
Figure 48. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country in 2021
Figure 49. Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 50. France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 51. UK Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 52. Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 53. Russia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 54. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country in 2021
Figure 55. Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country in 2021
Figure 56. Egypt Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 57. South Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 58. Israel Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 59. Turkey Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 60. GCC Country Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 61. Manufacturing Cost Structure Analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in 2021
Figure 62. Manufacturing Process Analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Figure 63. Industry Chain Structure of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
Figure 64. Channels of Distribution
Figure 65. Distributors Profiles
